A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma

Trial Profile

A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs X4P 001 (Primary) ; Axitinib
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Sponsors X4 Pharmaceuticals
  • Most Recent Events

    • 30 Oct 2017 According to an X4 pharmaceuticals media release, Phase I dose escalation part completed and enrollment in Phase II expansion part continues.
    • 30 Oct 2017 Updated results from phase I part were presented in a X4 pharmaceuticals media release.
    • 25 Oct 2017 Results of phase1 portion of dose-finding of X4P-001 and axitinib in patient patients with advanced renal cell carcinoma, were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top